2023
Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants
Moriyama M, Lucas C, Monteiro V, Initiative Y, Iwasaki A, Chen N, Breban M, Hahn A, Pham K, Koch T, Chaguza C, Tikhonova I, Castaldi C, Mane S, De Kumar B, Ferguson D, Kerantzas N, Peaper D, Landry M, Schulz W, Vogels C, Grubaugh N. Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2221652120. PMID: 37036977, PMCID: PMC10120007, DOI: 10.1073/pnas.2221652120.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, NeutralizingAntibodies, ViralBreakthrough InfectionsCOVID-19HumansReinfectionSARS-CoV-2Spike Glycoprotein, CoronavirusConceptsMHC-I expressionBreakthrough infectionsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantsMajor histocompatibility complex class I expressionCell-mediated immunityInfluenza virus infectionSARS-CoV-2 VOCsMHC-I upregulationClass I expressionSARS-CoV-2T cell recognitionVirus infectionMHC II expressionSpike proteinEnhanced inhibitionInfectionCell recognitionCommon mutationsReinfectionE proteinAntibodiesViral genesSubvariantsExpression
2021
Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection
Nagai M, Moriyama M, Ichinohe T. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection. MBio 2021, 12: 10.1128/mbio.01598-21. PMID: 34399617, PMCID: PMC8406166, DOI: 10.1128/mbio.01598-21.Peer-Reviewed Original ResearchMeSH KeywordsAdaptive ImmunityAdjuvants, ImmunologicAdministration, IntranasalAnimalsAntibodies, ViralBacteriaCell LineChlorocebus aethiopsCOVID-19COVID-19 VaccinesDogsHemagglutinin Glycoproteins, Influenza VirusImmunity, MucosalInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesMadin Darby Canine Kidney CellsMiceMice, Inbred BALB CMyeloid Differentiation Factor 88Nasal MucosaOrthomyxoviridae InfectionsPathogen-Associated Molecular Pattern MoleculesSARS-CoV-2VaccinationVero CellsConceptsInfluenza virus infectionVirus-specific adaptive immunityVaccine-specific antibody responseVirus-specific antibody responsesAntibody responseMyD88-dependent mannerVirus infectionHealthy human volunteersPathogen-associated molecular patternsImmune responseNasal bacteriaOral bacteriaCommensal bacteriaIntranasal supplementationHA vaccineVaccine protectsIntranasal vaccineIntranasal administrationIntranasal applicationAdaptive immunityOral cavityAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSevere acute respiratory syndrome coronavirus 2Influenza virus hemagglutinin vaccine
2017
Induction of lung CD8+ T cell responses by consecutive inoculations of a poly(I:C) influenza vaccine
Moriyama M, Takeyama H, Hasegawa H, Ichinohe T. Induction of lung CD8+ T cell responses by consecutive inoculations of a poly(I:C) influenza vaccine. Vaccine 2017, 35: 6620-6626. PMID: 29079103, DOI: 10.1016/j.vaccine.2017.10.038.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntranasalAnimalsAntibodies, ViralCD8-Positive T-LymphocytesCross ProtectionImmunoglobulin AInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesLungMiceMice, Inbred BALB COrthomyxoviridae InfectionsPoly I-CT-Lymphocytes, CytotoxicVaccinationVaccines, InactivatedConceptsMediastinal lymph nodesStrong CTL responsesCTL responsesIntranasal vaccinationInfluenza vaccineVirus vaccineInfluenza virus-specific CD8Cytotoxic T lymphocyte responsesInfluenza virusHeterologous influenza virusesVirus-specific CD8T lymphocyte responsesT cell responsesInfluenza virus infectionInfluenza virus vaccineWhole virus vaccineLung CD8Respiratory DCsVaccine elicitsLymph nodesLymphocyte responsesIntranasal administrationConsecutive vaccinationsT cellsVirus infectionConsecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge
Moriyama M, Chino S, Ichinohe T. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge. Vaccine 2017, 35: 1001-1007. PMID: 28111142, DOI: 10.1016/j.vaccine.2017.01.025.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntranasalAnimalsAntibodies, ViralCross ProtectionFemaleFormaldehydeImmunity, MucosalImmunization ScheduleImmunoglobulin AImmunoglobulin GInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza VaccinesMiceMice, Inbred BALB COrthomyxoviridae InfectionsPoly I-CSurvival AnalysisVaccines, InactivatedConceptsInfluenza virus vaccinePrimary immune responseVirus vaccineIntranasal vaccinationVirus challengeImmune responseInactivated influenza virus vaccineInfluenza virusHeterologous influenza virus challengeVirus-specific IgAInfluenza virus challengeHeterologous virus challengeNatural infectionSerum IgG responsesConsecutive inoculationsSingle intranasal vaccinationCross-protective activityNasal IgANasal washesIgG responsesMucosal immunitySystemic immunityVaccinationNaïve animalsVaccine